The outcomes of the Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS) trial have unequivocally proven that inflammation is a key driver of atherosclerosis and that targeting inflammation, in this case by using an anti-interleukin-1b antibody, improves cardiovascular disease (CVD) outcomes. This is especially true for CVD patients with a pro-inflammatory constitution. Although CANTOS has epitomized the importance of targeting inflammation in atherosclerosis, treatment with canakinumab did not improve CVD mortality, and caused an increase in infections. Therefore, the identification of novel drug targets and development of novel therapeutics that block atherosclerosis-specific inflammatory pathways and exhibit limited immune-sup...
The hypothesis of an inflammatory component in the pathogenesis of atherosclerosis has been under in...
As current therapies for cardiovascular disease (CVD), predominantly based on lipid lowering, still ...
Atherosclerosis is a chronic disease of the large arteries and the underlying cause of myocardial in...
The outcomes of the Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS) trial have unequ...
Inflammation is a critical pathway in the pathogenesis of atherosclerosis. Previous studies have sho...
IL-1 cytokines are mainly responsible for controlling a series of pro-inflammatory reactions induced...
The CANTOS trial (Canakinumab Anti-Inflammatory Thrombosis Outcome Study) provides intriguing suppor...
Background Inflammation contributes to all phases of the atherothrombotic process, and patients with...
Atherosclerosis is still a great burden on human health and scientific achievements of the past 30 y...
Inflammation has proven in multiple studies to be responsible for the progression of cardiometabolic...
BACKGROUND: Experimental and clinical data suggest that reducing inflammation without affecting lipi...
Atherosclerosis is a chronic inflammatory disorder of the vasculature where cholesterol accumulates ...
BACKGROUND Experimental and clinical data suggest that reducing inflammation without affecting lipid...
The hypothesis of an inflammatory component in the pathogenesis of atherosclerosis has been under in...
As current therapies for cardiovascular disease (CVD), predominantly based on lipid lowering, still ...
Atherosclerosis is a chronic disease of the large arteries and the underlying cause of myocardial in...
The outcomes of the Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS) trial have unequ...
Inflammation is a critical pathway in the pathogenesis of atherosclerosis. Previous studies have sho...
IL-1 cytokines are mainly responsible for controlling a series of pro-inflammatory reactions induced...
The CANTOS trial (Canakinumab Anti-Inflammatory Thrombosis Outcome Study) provides intriguing suppor...
Background Inflammation contributes to all phases of the atherothrombotic process, and patients with...
Atherosclerosis is still a great burden on human health and scientific achievements of the past 30 y...
Inflammation has proven in multiple studies to be responsible for the progression of cardiometabolic...
BACKGROUND: Experimental and clinical data suggest that reducing inflammation without affecting lipi...
Atherosclerosis is a chronic inflammatory disorder of the vasculature where cholesterol accumulates ...
BACKGROUND Experimental and clinical data suggest that reducing inflammation without affecting lipid...
The hypothesis of an inflammatory component in the pathogenesis of atherosclerosis has been under in...
As current therapies for cardiovascular disease (CVD), predominantly based on lipid lowering, still ...
Atherosclerosis is a chronic disease of the large arteries and the underlying cause of myocardial in...